Sorafenib can effectively block tumor angiogenesis in an HCC model and targets multiple receptor tyrosine kinases (RTKs), including vascular endothelial growth factor receptor (VEGFR)-2, platelet-derived growth factor receptor (PDGFR), FLT3, Ret, and c-Kit11. This evidence concerns the gene PDGFRB and hepatocellular carcinoma.